^
    Back
    Association details:
    Biomarker:RET V804M + RET M918T + RET G810 + RET Y806
    Cancer:Thyroid Gland Medullary Carcinoma
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    ESMO.org
    Title:

    Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

    Published date:
    04/11/2020
    Excerpt:
    RETG810C/S mutations at the solvent front and RETY806C/N mutation at the hinge region were found in cfDNAs of an MTC patient with RETM918T/V804M/L, who initially responded to selpercatinib and developed resistance.
    DOI:
    10.1016/j.annonc.2020.10.599